Local Postsurgical Targeted Therapy

About Postsurgical Therapeutics

Postsurgical Therapeutics is a private, pre-revenue biotech founded in 2014, leveraging its PLGA-based drug delivery platform to create locally administered, repurposed drugs. Its lead program, the CLOTT platform, targets advanced cancers via intra-tumor injection combined with systemic therapy, while other partnered programs address pain in hemophilic arthropathy and diabetic neuropathy. The company operates with a semi-virtual model under experienced leadership, having previously monetized assets through sales to Korean partners.

Therapeutic Areas